טוען...
T cell engaging bispecific antibody (T-BsAb): from technology to therapeutics
Harnessing the power of the human immune system to treat cancer is the essence of immunotherapy. Monoclonal antibodies engage the innate immune system to destroy targeted cells. For the last 30 years, antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity have been the m...
שמור ב:
| הוצא לאור ב: | Pharmacol Ther |
|---|---|
| Main Authors: | , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
2017
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5785550/ https://ncbi.nlm.nih.gov/pubmed/28834699 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.pharmthera.2017.08.005 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|